Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/ID4QZtayZnE/250937.php
Tuesday, 2 October 2012
SMi's 6th Annual Biomarkers Summit - Innovations Is Stratified Medicine, 16-17 January 2013, London
The drive towards personalized medicine is seeing pharma move from patient stratification as a 'nice to have', to an essential feature of product development. Exemplified by the success of Herceptin, biomarkers promise to transform drug discovery, clinical development and diagnostics in the R&D process. This dynamic market, poised to reach a value of $33.3 billion by 2015, will continue to improve decision-making, clinical trial success rates and translational productivity...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment